ADMP Adamis Pharmaceuticals Corporation

5.10
-0.05  -1%
Previous Close 5.15
Open 5.10
Price To book 4.72
Market Cap 159891803
Shares 31,351,334
Volume 359,514
Short Ratio 6.48
Av. Daily Volume 518,790

SEC filingsSee all SEC filings

  1. 424B3 - Prospectus [Rule 424(b)(3)] 171043917
  2. 424B3 - Prospectus [Rule 424(b)(3)] 171043910
  3. 8-K - Current report 171042148
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030165
  5. 424B3 - Prospectus [Rule 424(b)(3)] 17974733

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
Epinephrine Pre-filled Syringe (PFS)
Emergency treatment of anaphylaxis.
Phase 3 IND to be submitted 1H 2017.
APC-3000
Allergic Rhinitis
Phase 3 planned
APC-1000
Asthma/COPD

SEC Filings

  1. 424B3 - Prospectus [Rule 424(b)(3)] 171043917
  2. 424B3 - Prospectus [Rule 424(b)(3)] 171043910
  3. 8-K - Current report 171042148
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030165
  5. 424B3 - Prospectus [Rule 424(b)(3)] 17974733
  6. 8-K - Current report 17973452
  7. S-8 - Securities to be offered to employees in employee benefit plans 17928184
  8. 8-K - Current report 17914328
  9. 8-K - Current report 17906451
  10. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17855276